Asian shares are trading mostly higher after a Wall Street rally that followed profit reports from major companies ...

Adding the PCSK9 inhibitor led to greater absolute reductions in CVD risk than in younger patients, with no signs of safety ...

Amgen stock rose early Wednesday, though the biotech behemoth said the FDA placed one of its obesity treatments on clinical ...

Erste Group analyst Hans Engel upgraded Amgen (AMGN) to Buy from Hold. Amgen has a higher operating margin and a higher return on equity than ...

Most of the Dow Jones is testing into the high side as broad-market sentiment generally improves. Familiar market favorites Amgen (AMGN) and Nvidia (NVDA) are climbing on Wednesday, gaining 5.5% and 4 ...

Amgen's Q4 earnings beat expectations, showcasing robust performance for the company's growth strategy. Click here to read ...

The Dow Jones Industrial Average is climbing Wednesday afternoon with shares of Amgen and NVIDIA Corp. seeing positive growth for the index.

What Happened? Shares of biotech company Amgen (NASDAQ:AMGN) jumped 5.3% in the morning session after the company reported ...

Alexion Pharmaceuticals v Amgen (UPC_Coa-405/2024) and Alexion Pharmaceuticals v Samsung Bioepis NL BV (UPC_CoA-402/2024); December 20, 2024.

The FDA has paused a study of Amgen’s early-stage candidate AMG 513. Elsewhere, Valneva got another approval and a radiopharma developer raised $112 million.

The Dow Dow Jones Industrial Average was most recently trading 148 points (0.3%) higher, as shares of Amgen Amgen Inc. and NVIDIA Corp. NVIDIA Corp. are contributing to the index's intraday rally.

Sales of the firm's bispecific T-cell engager Blincyto increased more than 50 percent from the fourth quarter of 2023 to 2024.